Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Oncology Strategy: The Long Game Comes Into Focus

Executive Summary

Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.

Advertisement

Related Content

Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Roche's Guide To Success In Oncology
For Roche Immuno-Oncology, It’s Steady As She Goes
Merck Is Finding PD-L1 Testing Is Helping Keytruda
Roche’s PD-L1 Bladder Cancer Data Show Promise Of New Biomarkers
Roche Gets Atezolizumab Applications Rolling
Roche R&D Operations Controlled By 'Go … Wait … Or Gate'
Companion Diagnostics Come Of Age
Roche Could Repeat Genentech Success With Foundation Medicine Partnership

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS056928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel